Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.

View in: PubMed

subject areas

Animals
Antibodies, Monoclonal
Cell Line, Tumor
Humans
Immunodominant Epitopes
Immunotherapy
Mice
Mice, Inbred C57BL
Mouth Neoplasms
Neoadjuvant Therapy
Programmed Cell Death 1 Receptor
T-Lymphocytes
Tumor Microenvironment
Xenograft Model Antitumor Assays

authors with profiles

Hans Schreiber